Tumour necrosis factor receptor-associated periodic syndrome caused by a rare mutation in the TNFRSF1A gene, and with excellent response to etanercept treatment
Cantarini, L.; Lucherini, O.M.; Galeazzi, M.; Fanti, F.; Simonini, G.; Baldari, C.T.; Laghi Pasini, F.; De Martino, M.; Cimaz, R.
Clinical and Experimental Rheumatology 27(5): 890-891
2009
ISSN/ISBN: 0392-856X PMID: 19917181 Document Number: 630660
Document emailed within 1 workday
Related Documents
Cantarini, L.; Lucherini, O.M.; Cimaz, R.; Galeazzi, M. 2010: Recurrent pericarditis caused by a rare mutation in the TNFRSF1A gene and with excellent response to anakinra treatment Clinical and Experimental Rheumatology 28(5): 802De Filippis, L.; Caliri, A.; Anghelone, S.; Scibilia, G.; Lo Gullo, R.; Bagnato, G. 2006: Improving outcomes in tumour necrosis factor a treatment: comparison of the efficacy of the tumour necrosis factor a blocking agents etanercept and infliximab in patients with active rheumatoid arthritis Panminerva Medica 48(2): 129-135
Lucherini, O.M.; Vitale, A.; Obici, L.; Sota, J.; Frediani, B.; Merlini, G.; Rigante, D.; Cantarini, L. 2019: Differential serum levels of interleukin-37 in patients with tumour necrosis factor receptor-associated periodic syndrome (TRAPS) Clinical and Experimental Rheumatology 37 Suppl 121(6): 159-160
Simon, A.; Drenth, J.P.; van der Meer, J.W. 2001: From gene to disease; tumor necrosis factor receptor and a syndrome of familial periodic fever Nederlands Tijdschrift Voor Geneeskunde 145(2): 77-78
Dinc, A.; Erdem, H.; Rowczenio, D.; Simsek, I.; Pay, S.; Bahce, M.; Lachmann, H. 2005: Autosomal dominant periodic fever with AA amyloidosis: tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in a Turkish family Journal of Nephrology 18(5): 626-629
Sundrarjun, T.; Komindr, S.; Archararit, N.; Dahlan, W.; Puchaiwatananon, O.; Angthararak, S.; Udomsuppayakul, U.; Chuncharunee, S. 2004: Effects of n-3 fatty acids on serum interleukin-6, tumour necrosis factor-alpha and soluble tumour necrosis factor receptor p55 in active rheumatoid arthritis Journal of International Medical Research 32(5): 443-454
Alvarez-Lobos, M.; Hunter, B.; Cofré, C.; Benítez, C.; Talesnik, E.; Oyarzo, M.; Aróstegui, J.I.; Yagüe, J. 2006: Tumor necrosis factor receptor associated periodic syndrome (TRAPS). Report of two cases Revista Medica de Chile 134(12): 1558-1561
Celebi-Tayfur, Aı.; Bilginer, Y.; Finetti, M.; Gattorno, M.; Ozen, S. 2013: Different presentations in patients with tumor necrosis factor receptor-associated periodic syndrome mutations: report of two cases Turkish Journal of Pediatrics 55(1): 78-81
Fujikawa, K.; Kawakami, A.; Eguchi, K. 2007: Etanercept: recombinant human soluble tumor necrosis factor receptor fusion protein Nihon Rinsho. Japanese Journal of Clinical Medicine 65(7): 1211-1217
Brakebusch, C.; Nophar, Y.; Kemper, O.; Engelmann, H.; Wallach, D. 1992: Cytoplasmic truncation of the p55 tumour necrosis factor (TNF) receptor abolishes signalling, but not induced shedding of the receptor EMBO Journal 11(3): 943-950
Elias-Assad, G.; Elias, M.; Kanety, H.; Pressman, A.; Tenenbaum-Rakover, Y. 2016: Persistent Müllerian Duct Syndrome Caused by a Novel Mutation of an Anti-MüIlerian Hormone Receptor Gene: Case Presentation and Literature Review Pediatric Endocrinology Reviews: Per 13(4): 731-740
Juhl, P.; Thudium, C.S.; Gudmann, N.S.; Karsdal, M.A.; Bay-Jensen, A.-C.; Siebuhr, A.S. 2018: IL-6 receptor inhibition modulates type IIi collagen and C-reactive protein degradation in rheumatoid arthritis patients with an inadequate response to anti-tumour necrosis factor therapy: analysis of connective tissue turnover in the tocilizumab RADIATE study Clinical and Experimental Rheumatology 36(4): 568-574
Adachi, M. 2008: Case of a Japanese female presenting severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN) syndrome with a K650M mutation in the fibroblast growth factor receptor 3 gene No to Hattatsu 40(6): 478-482
Rémy, A.; Avouac, J.; Gossec, L.; Combe, B. 2011: Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis Clinical and Experimental Rheumatology 29(1): 96-103
Sato, T.; Yamauchi, N.; Sasaki, H.; Takahashi, M.; Okamoto, T.; Sakamaki, S.; Watanabe, N.; Niitsu, Y. 1998: An apoptosis-inducing gene therapy for pancreatic cancer with a combination of 55-kDa tumor necrosis factor (TNF) receptor gene transfection and mutein TNF administration Cancer Research 58(8): 1677-1683
Braczkowski, R.; Zubelewicz, B.; Romanowski, W.; Lissoni, P.; Brivio, F. 1998: Possible biological indicators of the response to recombinant tumour necrosis factor alpha in patients with advanced neoplasms Journal of Experimental and Clinical Cancer Research: Cr 17(3): 349-354
Browne, W.L.; Wilson, W.R.; Baguley, B.C.; Ching, L.M. 1998: Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid Anticancer Research 18(6a): 4409-4413
Zu, F.; Bi, Y.; Yao, X.; Wang, H.; Zhou, L.; Li, N. 2014: An association study of six-transmembrane protein of prostate 2 gene with metabolic index and tumour necrosis factor in Uygur population Zhonghua Nei Ke Za Zhi 53(2): 131-134
Pussieldi, G.A.; Gomes, E.C.; Veneroso, C.E.; De Paz, J.A.; Fonseca, T.R.; Mendes, T.T.; Rossi, A.G.; Teixeira, M.M.; Teixeira, A.L.; Alessandri, A.L. 2014: Soluble tumour necrosis factor receptor-1 (sTNFR1) levels are positively associated with exercise intensity in athletes after strenuous off-road cycling Journal of Sports Medicine and Physical Fitness 54(2): 225-231
Rahier, J.F.; Lion, L.; Dewit, O.; Lambert, M. 2005: Regression of Sweet's syndrome associated with Crohn's disease after anti-Tumour Necrosis Factor therapy Acta Gastro-Enterologica Belgica 68(3): 376-379